Compare Cytokinetics Inc (CYTK) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Suncor Energy Inc. — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Suncor Energy Inc. trades at $60.62 (market cap $71.44B). The key difference: Suncor Energy Inc. is far larger — about 6.4× Cytokinetics Inc's market cap, and Suncor Energy Inc. pays a 2.76% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | SU | |
|---|---|---|
Market Cap | $11.12B | $71.44B |
Sector | Technology | Energy |
52-Week High | $87.26 | $69.73 |
52-Week Low | $33.23 | $38.17 |
Enterprise Value | $11.59B | $79.57B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Suncor Energy (SU) trades at $61.27, up 3.41% with strong bullish momentum. The stock shows robust fundamentals with a P/E of 16.54, net margin of 11.62%, and consistent dividend payments. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 slightly missed. Technical indicators signal bullish sentiment with the current price near resistance at $62. Analyst consensus is strongly positive with 74% buy ratings.
SU presents a compelling investment case with attractive valuation metrics and strong profitability. However, investors face risks from oil price volatility and recent operational challenges. The company's disciplined capital allocation and record production support long-term value, but macroeconomic headwinds and competitive pressures require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
